Asunaprevir
Trials 37 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 6 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02045693 Background | Feb → Apr 2014 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01063023 Comparator | Jan → Jun 2010 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01019070 Comparator | Dec 2009 → Aug 2011 | liver disorder | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00722358 Comparator | Dec 2008 → Dec 2009 | chronic hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02496078 Comparator | Aug 2015 → Aug 2016 | chronic hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT02123654 Comparator | Apr 2014 → Jan 2015 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2012-04-19 | Bristol-Myers Squibb | All-Oral Hepatitis C Virus Treatment with Bristol-Myers Squibb’s Investigational Compounds Daclatasvir and Asunaprevir Achieved Sustained Virologic Response in 77% of Difficult-to-Treat Patients bms.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 49 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Asunaprevir | “Chinese patients with chronic HCV genotype 1b infection without cirrhosis were randomly allocated by a computer program to one of three treatment groups (sofosbuvir,...” PMID 27917405 ↗ Jul 201632“All participants will each receive daclatasvir (30mg), asunaprevir (200mg) and beclabuvir (75mg) in a fixed-dose combination oral tablet for twice daily administration with food.” NCT02292966 ↗ “To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet” NCT02108639 ↗ “Fixed dose combination (daclatasvir \[DCV\] 30 milligrams, asunaprevir \[ASV\] 200 milligrams, and BMS-791325 75 milligrams) one tablet administered twice daily” NCT02175602 ↗ “DCV 3DAA FDC (Daclatasvir 30 mg/Asunaprevir 200 mg/BMS-791325 75 mg 3 direct-acting antiviral (3DAA) fixed dose combination tablet) orally twice daily” NCT02045693 ↗ “Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C.” PMID 25038486 ↗ Jul 2014 “Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 12 weeks” NCT01979939 ↗ “DCV 30 mg (as the free base) / Asunaprevir (ASV) 200 mg / BMS-791325 75 mg FDC tablet orally twice daily for 12 weeks” NCT02170727 ↗ “Daclatasvir (DCV), Asunaprevir (ASV), BMS-791325 and Sofosbuvir is effective and safe in treating Hepatitis-C virus.” NCT02175966 ↗ “Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) orally twice a day” NCT02098616 ↗ “Fixed Dose Combination of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325” NCT02095860 ↗ “Asunaprevir (ASV) 200mg administered orally twice daily” NCT03794258 ↗ “Asunaprevir (ASV) 200mg administered orally twice daily” NCT02583685 ↗ “Asunaprevir and Daclatsvir” NCT01888900 ↗ |
| Known as | ASV | “To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet” NCT02108639 ↗16“We evaluated the efficacy and safety of daclatasvir (DCV) and asunaprevir (ASV) in patients with chronic hepatitis C virus (HCV) infection on hemodialysis.” PMID 30400729 ↗ Mar 2019 “The efficacy of daclatasvir (DCV), asunaprevir (ASV), pegylated interferon and ribavirin (Peg-IFN/RBV) association was investigated in these patients.” PMID 29271782 ↗ Mar 2018 “Oral treatment with Asunaprevir 100mg (ASV), twice daily, and Daclatasvir 60mg (DCV), once daily, for 24 weeks in HIV/HCV genotype 1b patients” NCT02124044 ↗ “UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination” NCT01979939 ↗ “whether a rapid reduction in viremia by daclatasvir (DCV) and asunaprevir (ASV) improves the response to pegylated interferon” PMID 26733671 ↗ Jan 2016 “DCV 30 mg (as the free base) / Asunaprevir (ASV) 200 mg / BMS-791325 75 mg FDC tablet orally twice daily for 12 weeks” NCT02170727 ↗ “Daclatasvir (DCV), Asunaprevir (ASV), BMS-791325 and Sofosbuvir is effective and safe in treating Hepatitis-C virus.” NCT02175966 ↗ “The combination of daclatasvir (DCV, pan-genotypic NS5A inhibitor) plus asunaprevir (ASV; NS3 protease inhibitor)” PMID 27287851 ↗ Jun 2016 “Fixed Dose Combination of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325” NCT02095860 ↗ “Asunaprevir (ASV) and Daclatasvir (DCV) to Telaprevir (TVR) included therapy” NCT01718145 ↗ “Asunaprevir (ASV) 200mg, administered orally twice daily.” NCT02470858 ↗ “Asunaprevir (ASV) 200mg administered orally twice daily” NCT03794258 ↗ “Asunaprevir (ASV) 200mg administered orally twice daily” NCT02583685 ↗ “Daclatasvir (DCV)/Asunaprevir (ASV)/BMS-791325” NCT02123654 ↗ “asunaprevir \[ASV\]” NCT02175602 ↗ “Asunaprevir (ASV)” NCT01581203 ↗ |
| Known as | BMS-650032 | “BMS-650032 (Asunaprevir)” NCT01497834 ↗ |
| Known as | Sunvepra | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02639585 ↗ |
| Action | Inhibit | “Asunaprevir is a selective HCV NS3 protease inhibitor” PMID 25038486 ↗ Jul 2014 |
| Modality | Small molecule | — CHEMBL2105735 ↗ |
| Route | Oral | “single oral doses of BMS-650032” NCT00559247 ↗ |